WELCOME TO iNANOD
AI-BACKED RAPID TARGETED CANCER CHEMO-IMMUNOTHERAPY
WHAT WE DO
.png)
At iNANOD, we aim to make cancer treatment smarter. Our target is to leverage the dual action of monoclonal antibodies—achieving superior receptor binding for precise adherence while driving cellular internalization to trigger a powerful immune response. Our future goals focus on bridging the gap between the lab and clinical success.
ABOUT
iNANOD AS is a growing micro-pharma within the prestigious Oslo Cancer Cluster. iNANOD is redefining oncology with a "double-hit" platform that synchronizes high-precision chemotherapy with advanced immunotherapy. While standard treatments may realize only a fraction of their potential, our target is to shatter the status quo. We aim to increase the injected dose (ID%) reaching solid tumours from an industry average of 1% to 20%. Our future goals are clear: maximize treatment efficacy and redefine the ceiling of oncology performance.
After successful in silico studies, we aim to advance pre-clinical (proof-of-principle) studies, marking our transition to a high-value development phase. While results may vary at this stage, we have successfully identified our primary therapeutic target. With our next major valuation milestone approaching and our future goals set on expanding our pipeline, the window for early-stage participation is narrowing. Partner with us today to lead the future of cancer care.
THE PEOPLE
BOARD MEMBERS
Åge Nærdal
Chairman
Trained as a Pharmacist having more than 35 years of experience in leadership from pharmaceutical industry.
Stener Kvinnsland
Board member
MD with a PhD in oncology. Various roles in the pharmaceutical an biotech industry, former COB at Oslo University Hospital, former MD of Helse Bergen and former Director at Haukeland University Hospital. Specialist and professor in cancer medicine.
Per Foss
Board member
Bio-organic chemistry doctorate having hugely diverse professional expertise in the industry.
Nalinava Sengupta
Board Member & CEO
After 15 years of academic research in chemistry, turned entrepreneur for a mission.
Thomas Due
Board member
He has over 20 years of Innovation and Venture Capital Fundraising experience in Norway. He has spent most of his adult life working where finance meets entrepreneurs.
SUPPORTERS
MEMBER OF
